Andrew P Brown
Overview
Explore the profile of Andrew P Brown including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1479
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hobor S, Al Bakir M, Hiley C, Skrzypski M, Frankell A, Bakker B, et al.
Nat Commun
. 2024 Jun;
15(1):4871.
PMID: 38871738
The phenomenon of mixed/heterogenous treatment responses to cancer therapies within an individual patient presents a challenging clinical scenario. Furthermore, the molecular basis of mixed intra-patient tumor responses remains unclear. Here,...
2.
Murphy P, Galette P, Van der Aart J, Janiczek R, Patel N, Brown A
Br J Radiol
. 2023 Jul;
96(1150):20211126.
PMID: 37393537
In 2008, the role of clinical imaging in oncology drug development was reviewed. The review outlined where imaging was being applied and considered the diverse demands across the phases of...
3.
Ekman S, Cselenyi Z, Varrone A, Jucaite A, Martin H, Schou M, et al.
Clin Transl Sci
. 2023 Feb;
16(6):955-965.
PMID: 36808835
Brain metastases (BMs) are associated with poor prognosis in epidermal growth factor receptor mutation-positive (EGFRm) non-small cell lung cancer (NSCLC). Osimertinib is a third-generation, irreversible, EGFR-tyrosine kinase inhibitor that potently...
4.
Ahn M, Chiu C, Cheng Y, Han J, Goldberg S, Greystoke A, et al.
J Thorac Oncol
. 2019 Dec;
15(4):637-648.
PMID: 31887431
Introduction: Osimertinib has shown promising activity in patients with leptomeningeal metastases (LMs) of EGFR-positive NSCLC at 160 mg once daily (qd) (BLOOM; NCT02228369). We report LM activity with osimertinib (80...
5.
Yang J, Kim S, Kim D, Lee J, Cho B, Ahn J, et al.
J Clin Oncol
. 2019 Dec;
38(6):538-547.
PMID: 31809241
Purpose: In this phase I study (BLOOM), osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was evaluated in patients with leptomeningeal metastases (LMs) from EGFR-mutated (EGFRm)...
6.
Soltanahmadi S, Charpentier T, Nedelcu I, Khetan V, Morina A, Freeman H, et al.
ACS Appl Mater Interfaces
. 2019 Oct;
11(44):41676-41687.
PMID: 31609570
In wind turbine gearboxes, (near-)surface initiated fatigue is attributed to be the primary failure mechanism. In this work, the surface fatigue of a hydrogenated tungsten carbide/amorphous carbon (WC/aC:H) thin-film was...
7.
Varrone A, Varnas K, Jucaite A, Cselenyi Z, Johnstrom P, Schou M, et al.
J Cereb Blood Flow Metab
. 2019 Apr;
40(4):799-807.
PMID: 31006308
Osimertinib is a tyrosine kinase inhibitor (TKI) of the mutated epidermal growth factor receptor (EGFRm) with observed efficacy in patients with brain metastases. Brain exposure and drug distribution in tumor...
8.
Brown A, Denison F
Early Hum Dev
. 2018 Sep;
126:18-22.
PMID: 30241898
Group B streptococcus (GBS) is the most common cause of early-onset neonatal sepsis in many countries and responsible for significant perinatal morbidity and mortality worldwide. Intrapartum antibiotic prophylaxis has been...
9.
Reungwetwattana T, Nakagawa K, Cho B, Cobo M, Cho E, Bertolini A, et al.
J Clin Oncol
. 2018 Aug;
:JCO2018783118.
PMID: 30153097
Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated advanced non-small-cell lung cancer from the...
10.
Wu Y, Ahn M, Garassino M, Han J, Katakami N, Kim H, et al.
J Clin Oncol
. 2018 Jul;
36(26):2702-2709.
PMID: 30059262
Purpose In patients with epidermal growth factor receptor ( EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC), there is an unmet need for EGFR-tyrosine kinase inhibitors with improved CNS penetration and...